Dyadic International (DYAI) Other Non Operating Income (2018 - 2026)
Dyadic International (DYAI) posted Other Non Operating Income of $9591.0 for Q1 2026, up 235.62% sequentially from -$7072.0 in Q1 2025, and up 235.62% YoY from $2857.7 in Q1 2025.
Dyadic International (DYAI) Other Non Operating Income (2018 - 2026) Analysis & Trends
Dyadic International has reported Other Non Operating Income for 9 years, with the latest figure at $9591.0 in Q1 2026.
- Quarterly Other Non Operating Income rose 235.62% year-over-year to $9591.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$11993.0 (up 51.5% YoY) and the FY2024 annual result came in at -$22561.0, up 41.27% from the prior year.
- Other Non Operating Income rose to $9591.0 in Q1 2026 per DYAI's latest filing, from -$7072.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at $273578.0 in Q4 2022 and troughed at -$20621.0 in Q2 2022.
- A 5-year average of $34192.2 and a median of -$5995.0 in 2024 frame the typical range for Other Non Operating Income.
- The sharpest annual moves came in 2024 and 2026: Other Non Operating Income plunged 3008.39% in 2024, then jumped 235.62% in 2026.
- Over 5 years, Other Non Operating Income stood at $273578.0 in 2022, then plunged by 100.1% to -$274.0 in 2023, then slumped by 3008.39% to -$8517.0 in 2024, then increased by 16.97% to -$7072.0 in 2025, then surged by 235.62% to $9591.0 in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $9591.0, -$7072.0, and -$8517.0 for Q1 2026, Q1 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Dyadic International | 19.98 Mn | 19.98 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9,591.00 |
| Mar 31, 2025 | -7,072.00 |
| Dec 31, 2024 | -8,517.00 |
| Sep 30, 2024 | -5,995.00 |
| Jun 30, 2024 | -3,146.00 |
| Mar 31, 2024 | -4,903.00 |
| Dec 31, 2023 | -274.00 |
| Sep 30, 2023 | -12,600.00 |
| Jun 30, 2023 | -14,521.00 |
| Mar 31, 2023 | -11,022.00 |
| Dec 31, 2022 | 273,578.00 |
| Jun 30, 2022 | -20,621.00 |
| Mar 31, 2022 | 250,000.00 |
| Sep 30, 2021 | 1.65 Mn |
| Mar 31, 2021 | -28.27 Mn |
| Dec 31, 2020 | -62,345.00 |
| Jun 30, 2020 | -31,690.00 |
| Mar 31, 2020 | -10,867.00 |
| Dec 31, 2019 | -3,032.00 |
| Sep 30, 2019 | -13,727.00 |